The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients

NCT05938712 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Kidney Transplant Recipients

Interventions

DRUG: Dapagliflozin 10 MG
DRUG: Semaglutide, 1.0 mg/mL

Sponsor

University Health Network, Toronto